Safety and feasibility of physical therapy in cytopenic patients during allogeneic haematopoietic stem cell transplantation. (18th December 2012)

• Record Type: Journal Article
• Authors: Morishita, S.; Kaida, K.; Setogawa, K.; Kajihara, K.; Ishii, S.; Ikegame, K.; Kodama, N.; Ogawa, H.; Domen, K.
• Is Part Of: European journal of cancer care. Volume 22:Number 3(2013)
• Page Start: 289
• Page End: 299
• Publication Date: 2012-12-18
• Subjects: allogeneic haematopoietic stem cell transplantation -- physical therapy -- safety and feasibility -- cytopenia; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.12027
• Languages: English
• ISSNs: 0961-5423

Abstract

Safety and feasibility of physical therapy in cytopenic patients during allogeneic haematopoietic stem cell transplantation: This study aimed to investigate the safety and feasibility of physical therapy in cytopenic patients undergoing allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and to investigate the effect of physical therapy on physiological functions and quality of life (QOL) in allo‐HSCT patients. The study cohort included 321 patients who underwent allo‐HSCT. To investigate the safety and feasibility of physical therapy during cytopenia, patients were assigned to the physical therapy group ( n = 227) or the control group ( n = 94). To determine the effects of physical therapy, patients were divided according to the frequency with which they underwent physical therapy ( n = 51 per group). Handgrip strength, knee extensor strength and a 6‐min walk test were used as measures of physiological function. Short‐Form 36 was used to assess QOL. The physical therapy group had higher rate of achieving engraftment and lower death rate than the control group ( P < 0.05). After HSCT, the high‐frequency physical therapy group showed significantly less decline than the low‐frequency physical therapy group with respect to physical functioning of QOL ( P < 0.01). Physical therapy is quite beneficial and can be performed safely and feasibly in cytopenic patients during allo‐HSCT.